Memorial Sloan Kettering Cancer Center
Lecture Summary - ASCO 2022 Targeting HER2 Mutation-Positive Advanced Biliary Tract Cancers With Neratinib: Final Results From the Phase 2 SUMMIT Basket Trial
By
ASCO 2022 Conference Coverage
FEATURING
James Harding
By
ASCO 2022 Conference Coverage
FEATURING
James Harding
Login to view comments.
Click here to Login